Context Sensitive Modeling of Cancer Drug Sensitivity

Recent screening of drug sensitivity in large panels of cancer cell lines provides a valuable resource towards developing algorithms that predict drug response. Since more samples provide increased statistical power, most approaches to prediction of drug sensitivity pool multiple cancer types together without distinction. However, pan-cancer results can be misleading due to the confounding effects of tissues or cancer subtypes. On the other hand, independent analysis for each cancer-type is hampered by small sample size. To balance this trade-off, we present CHER (Contextual Heterogeneity Enabled Regression), an algorithm that builds predictive models for drug sensitivity by selecting predictive genomic features and deciding which ones should—and should not—be shared across different cancers, tissues and drugs. CHER provides significantly more accurate models of drug sensitivity than comparable elastic-net-based models. Moreover, CHER provides better insight into the underlying biological processes by finding a sparse set of shared and type-specific genomic features.

[1]  Janos X. Binder,et al.  DISEASES: Text mining and data integration of disease–gene associations , 2014, bioRxiv.

[2]  Nci Dream Community A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .

[3]  Gajendra P. S. Raghava,et al.  Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients , 2014, Scientific Reports.

[4]  Laura M. Heiser,et al.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.

[5]  Carlotta Costa,et al.  PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 , 2013, Proceedings of the National Academy of Sciences.

[6]  Tao Xu,et al.  Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..

[7]  Stacey Price,et al.  A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention , 2013, Cancer cell.

[8]  Howard L McLeod,et al.  Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed , 2013, Science.

[9]  R. Radinsky,et al.  Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab , 2013, PloS one.

[10]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[11]  A. Heck,et al.  Next-generation proteomics: towards an integrative view of proteome dynamics , 2012, Nature Reviews Genetics.

[12]  S. Novello,et al.  Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972) , 2012 .

[13]  S. Novello,et al.  Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab , 2012, British Journal of Cancer.

[14]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[15]  Y. Samuels,et al.  Molecular Pathways: Dysregulated Glutamatergic Signaling Pathways in Cancer , 2012, Clinical Cancer Research.

[16]  Chris Jones,et al.  Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition , 2012, Proceedings of the National Academy of Sciences.

[17]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[18]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[19]  R. Ophoff,et al.  Unraveling the Regulatory Mechanisms Underlying Tissue-Dependent Genetic Variation of Gene Expression , 2012, PLoS genetics.

[20]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[21]  M. Spiliotaki,et al.  Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. , 2011, Lung cancer.

[22]  Y. Ohe,et al.  Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer , 2011, Investigational New Drugs.

[23]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[24]  R. Tibshirani,et al.  Regression shrinkage and selection via the lasso: a retrospective , 2011 .

[25]  R. J. Anto,et al.  Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. , 2011, The international journal of biochemistry & cell biology.

[26]  Dean P. Foster,et al.  Minimum Description Length Penalization for Group and Multi-Task Sparse Learning , 2011, J. Mach. Learn. Res..

[27]  Simon C. Potter,et al.  The Architecture of Gene Regulatory Variation across Multiple Human Tissues: The MuTHER Study , 2011, PLoS genetics.

[28]  Alkes L. Price,et al.  Single-Tissue and Cross-Tissue Heritability of Gene Expression Via Identity-by-Descent in Related or Unrelated Individuals , 2011, PLoS genetics.

[29]  H. McLeod,et al.  Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application , 2011, The Journal of pathology.

[30]  Peter A. Jones,et al.  Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. , 2010, Cancer research.

[31]  A. Thorburn,et al.  The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models , 2010, Clinical Cancer Research.

[32]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[33]  G. Pagès,et al.  The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. , 2010, American journal of physiology. Cell physiology.

[34]  J. Desai,et al.  PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. , 2010 .

[35]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[36]  Dana Pe'er,et al.  Harnessing gene expression to identify the genetic basis of drug resistance , 2009, Molecular systems biology.

[37]  P. Deloukas,et al.  Common Regulatory Variation Impacts Gene Expression in a Cell Type–Dependent Manner , 2009, Science.

[38]  K. Patterson,et al.  Dual-specificity phosphatases: critical regulators with diverse cellular targets. , 2009, The Biochemical journal.

[39]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[40]  Sven Bergmann,et al.  A modular approach for integrative analysis of large-scale gene-expression and drug-response data , 2008, Nature Biotechnology.

[41]  P. Halban,et al.  Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-α and DUSP14 , 2008, Diabetes.

[42]  H. Findley,et al.  MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2 , 2008, Leukemia.

[43]  Carine Poussin,et al.  Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. , 2008, Diabetes.

[44]  Rajat Raina,et al.  Constructing informative priors using transfer learning , 2006, ICML.

[45]  J. Melo,et al.  BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry , 2006, Leukemia.

[46]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[47]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[48]  John H. Zhang,et al.  Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity , 2005, Neurological research.

[49]  Mina J Bissell,et al.  Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? , 2005, Cancer cell.

[50]  J. Testa,et al.  Inhibition of Inhibitor of Nuclear Factor-κB Phosphorylation Increases the Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models , 2004, Clinical Cancer Research.

[51]  D. Schrump,et al.  Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. , 2004, The Journal of thoracic and cardiovascular surgery.

[52]  Wei-Min Liu,et al.  Robust estimators for expression analysis , 2002, Bioinform..

[53]  W. Kolch,et al.  The role of MAPK pathways in the action of chemotherapeutic drugs. , 2002, Carcinogenesis.

[54]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[55]  Y. Yarden,et al.  Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 , 2001, Oncogene.

[56]  G. Sledge,et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide , 2000, Oncogene.

[57]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[58]  G. Sledge,et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. , 2000, Oncogene.

[59]  Jorma Rissanen,et al.  Hypothesis Selection and Testing by the MDL Principle , 1999, Comput. J..

[60]  R. Salgia,et al.  Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells , 1998, Leukemia.

[61]  D L Morton,et al.  Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. , 1997, The American journal of pathology.

[62]  R. Tibshirani Regression Shrinkage and Selection via the Lasso , 1996 .

[63]  Thomas M. Cover,et al.  Elements of Information Theory , 2005 .

[64]  J. Rissanen,et al.  Modeling By Shortest Data Description* , 1978, Autom..